Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joël Coste

Showing results (1-10 of 178) with videos related to

Pageof 18
Sort By:
La Revue Du Praticien|June 11, 2015
[From what did we suffer? What did we complain about in the Middle Ages?]Joël Coste
Pharmacoepidemiology and Drug Safety|February 28, 2017
Diverging approaches of pharmacovigilance and pharmacoepidemiology to assessing drug safety: epistemological and ethical implicationsJoël Coste
Medecine Sciences : M/S|April 10, 2015
[Illnesses and diseases in history: usefulness of their study for contemporary medicine and public health]Joël Coste
Medecine Sciences : M/S|March 21, 2025
[Contributions of Mirko Dražen Grmek to the history of medicine and biological science]Joël Coste
Canadian Bulletin of Medical History = Bulletin Canadien D'Histoire De La Medecine|September 19, 2017
Joël Coste
Rheumatology (Oxford, England)|August 2, 2016
Placebo-related effects: a meta-narrative review of conceptualization, mechanisms and their relevance in rheumatologyJoël Coste, Sébastien Montel
International Journal of Epidemiology|April 26, 2003
A grey zone for quantitative diagnostic and screening testsJoël Coste, Jacques Pouchot
BMC Medical Research Methodology|February 23, 2008
A methodological framework to distinguish spectrum effects from spectrum biases and to assess diagnostic and screening test accuracy for patient populations: application to the Papanicolaou cervical cancer smear testCaroline Elie, Joël Coste,
The New England Journal of Medicine|September 21, 2007
Adjuvant mitotane in adrenocortical carcinomaJérôme Bertherat, Joël Coste, Xavier Bertagna
Clinical Pharmacokinetics|June 5, 2019
Comment on: "Levothyrox<sup>®</sup> New and Old Formulations: Are they Switchable for Millions of Patients?"Joël Coste, Xavier Bertagna, Mahmoud Zureik
Pageof 18

Showing results (1-10 of 178) with videos related to

Sort By:
Pageof 18
La Revue Du Praticien|June 11, 2015
[From what did we suffer? What did we complain about in the Middle Ages?]Joël Coste
Pharmacoepidemiology and Drug Safety|February 28, 2017
Diverging approaches of pharmacovigilance and pharmacoepidemiology to assessing drug safety: epistemological and ethical implicationsJoël Coste
Medecine Sciences : M/S|April 10, 2015
[Illnesses and diseases in history: usefulness of their study for contemporary medicine and public health]Joël Coste
Medecine Sciences : M/S|March 21, 2025
[Contributions of Mirko Dražen Grmek to the history of medicine and biological science]Joël Coste
Canadian Bulletin of Medical History = Bulletin Canadien D'Histoire De La Medecine|September 19, 2017
Joël Coste
Rheumatology (Oxford, England)|August 2, 2016
Placebo-related effects: a meta-narrative review of conceptualization, mechanisms and their relevance in rheumatologyJoël Coste, Sébastien Montel
International Journal of Epidemiology|April 26, 2003
A grey zone for quantitative diagnostic and screening testsJoël Coste, Jacques Pouchot
BMC Medical Research Methodology|February 23, 2008
A methodological framework to distinguish spectrum effects from spectrum biases and to assess diagnostic and screening test accuracy for patient populations: application to the Papanicolaou cervical cancer smear testCaroline Elie, Joël Coste,
The New England Journal of Medicine|September 21, 2007
Adjuvant mitotane in adrenocortical carcinomaJérôme Bertherat, Joël Coste, Xavier Bertagna
Clinical Pharmacokinetics|June 5, 2019
Comment on: "Levothyrox<sup>®</sup> New and Old Formulations: Are they Switchable for Millions of Patients?"Joël Coste, Xavier Bertagna, Mahmoud Zureik
Pageof 18